Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer k | Cancer ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Gut microbiota composition may influence the efficacy and safety of chemo-immunotherapy in advanced non-small cell lung cancer. Read now.

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...